Delcath Systems’ (DCTH) “Buy” Rating Reiterated at HC Wainwright

HC Wainwright reiterated their buy rating on shares of Delcath Systems (NASDAQ:DCTH) in a research note issued to investors on Tuesday morning,Benzinga reports. The brokerage currently has a $22.00 price objective on the stock.

DCTH has been the subject of several other reports. StockNews.com raised Delcath Systems from a “sell” rating to a “hold” rating in a report on Friday, October 25th. Stephens reaffirmed a “buy” rating on shares of Delcath Systems in a research note on Friday, October 18th. Finally, Canaccord Genuity Group reissued a “buy” rating and issued a $21.00 target price on shares of Delcath Systems in a research report on Friday, October 18th. One research analyst has rated the stock with a hold rating and four have given a buy rating to the stock. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $21.50.

Delcath Systems Stock Performance

NASDAQ DCTH opened at $13.67 on Tuesday. The stock has a market capitalization of $437.03 million, a P/E ratio of -10.13 and a beta of 0.87. The business’s fifty day moving average is $11.36 and its two-hundred day moving average is $9.85. Delcath Systems has a 1 year low of $3.70 and a 1 year high of $14.10.

Institutional Investors Weigh In On Delcath Systems

Several hedge funds have recently bought and sold shares of the business. Polar Asset Management Partners Inc. purchased a new position in Delcath Systems during the 3rd quarter valued at about $1,594,000. Shellback Capital LP purchased a new stake in shares of Delcath Systems in the second quarter worth approximately $1,353,000. Principal Financial Group Inc. acquired a new stake in shares of Delcath Systems during the third quarter worth approximately $808,000. Renaissance Technologies LLC purchased a new position in Delcath Systems during the second quarter valued at approximately $694,000. Finally, Cubist Systematic Strategies LLC acquired a new position in Delcath Systems in the 2nd quarter valued at approximately $370,000. 61.12% of the stock is owned by hedge funds and other institutional investors.

About Delcath Systems

Delcath Systems, Inc, an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. The company’s lead product candidate is HEPZATO KIT, a melphalan for injection/hepatic delivery system to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects.